Skip to main content

Table 2 Association of clinical, pathological and genomic characteristics with PFS and OS in bevacizumab group

From: Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

Characteristics N
(111)
Progression Free Survival Overall Survival
    HR 95% CI P HR 95% CI p
Sex Females 54 1    1   
  Males 57 0.86 0.52-1.41 0.535 1.17 0.57-2.40 0.669
Age ≤ 65 years 64 1    1   
  >65 years 47 1.19 0.72-1.99 0.487 1.25 0.60-2.70 0.528
ECOG PS 0 102 1    1   
  1-2 9 0.95 0.43-2.04 0.877 0.42 0.18-1.45 0.207
Primary tumor Colon 82 1    1   
  Rectum 29 1.15 0.66-2.00 0.612 2.70 0.99-4.86 0.052
Mucinous histology No 96 1    1   
  Yes 15 2.16 1.23-7.12 0.015 3.21 1.99-14.98 0.001
Previous adjuvant CT No 66 1    1   
  Yes 45 1.84 1.17-3.37 0.011 1.25 0.60-2.69 0.531
Time to metastases Metachronous 50 1    1   
  Synchronous 61 0.67 0.40-1.09 0.103 0.93 0.44-1.95 0.849
No. of metastatic sites 1 57 1    1   
  >1 54 1.22 0.75-2.02 0.421 1.77 0.85-3.62 0.130
Liver-only metastases No 74 1    1   
  Yes 37 0.84 0.49-1.43 0.521 0.93 0.43-2.01 0.844
Resected primary tumor No 15 1    1   
  Yes 96 2.11 0.99-3.40 0.052 1.09 0.34-3.48 0.887
High LDH level No 69 1    1   
  Yes 31 0.86 0.48-1.50 0.574 1.41 0.64-3.26 0.376
  Unknown 11       
High CEA level No 86 1    1   
  Yes 23 0.69 0.39-1.20 0.183 0.65 0.28-1.61 0.375
  Unknown 2       
Low HgB level No 93 1    1   
  Yes 18 0.70 0.38-1.29 0.250 0.63 0.26-1.65 0.371
Leukocytosis No 102 1    1   
  Yes 9 1.29 0.55-3.19 0.526 2.43 0.84-17.91 0.083
High ALP level No 82 1    1   
  Yes 18 0.86 0.46-1.61 0.638 1.48 0.62-3.88 0.343
Low Albumin level No 89 1    1   
  Yes 8 0.93 0.38-2.30 0.874 1.25 0.26-6.43 0.757
  Unknown 14       
Köhne score Low 57 1    1   
  Intermediate-High 51 1.21 0.74-2.01 0.438 1.80 0.86-3.69 0.119
  Unknown 3       
-2578 A/A 16 1    1   
  A/C 60 1.02 0.50-2.07 0.959 1.19 0.41-3.38 0.753
  C/C 35 1.53 0.74-3.26 0.246 1.36 0.42-4.65 0.581
-1498 C/C 22 1    1   
  C/T 60 1.82 0.98-3.55 0.056 2.49 0.98-6.16 0.056
  T/T 29 2.65 1.49-6.62 0.003 2.47 0.91-7.76 0.074
+ 405 G/G 39 1    1   
  G/C 54 1.08 0.62-1.90 0.783 1.29 0.57-2.93 0.531
  C/C 18 1.11 0.52-2.39 0.771 1.36 0.47-4.12 0.544
+ 936 T/T 2 1    1   
  C/T 31 1.38 0.35-5.38 0.642 1.60 0.27-8.47 0.645
  C/C 78 1.04 0.25-4.35 0.955 1.39 0.23-7.96 0.741